Cheng S. Jin
University of Toronto
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cheng S. Jin.
Nature Materials | 2011
Jonathan F. Lovell; Cheng S. Jin; Elizabeth Huynh; Honglin Jin; Chulhong Kim; John L. Rubinstein; Warren C. W. Chan; Weiguo Cao; Lihong V. Wang; Gang Zheng
Optically active nanomaterials promise to advance a range of biophotonic techniques through nanoscale optical effects and integration of multiple imaging and therapeutic modalities. Here, we report the development of porphysomes; nanovesicles formed from self-assembled porphyrin bilayers that generated large, tunable extinction coefficients, structure-dependent fluorescence self-quenching and unique photothermal and photoacoustic properties. Porphysomes enabled the sensitive visualization of lymphatic systems using photoacoustic tomography. Near-infrared fluorescence generation could be restored on dissociation, creating opportunities for low-background fluorescence imaging. As a result of their organic nature, porphysomes were enzymatically biodegradable and induced minimal acute toxicity in mice with intravenous doses of 1,000 mg kg(-1). In a similar manner to liposomes, the large aqueous core of porphysomes could be passively or actively loaded. Following systemic administration, porphysomes accumulated in tumours of xenograft-bearing mice and laser irradiation induced photothermal tumour ablation. The optical properties and biocompatibility of porphysomes demonstrate the multimodal potential of organic nanoparticles for biophotonic imaging and therapy.
ACS Nano | 2013
Cheng S. Jin; Jonathan F. Lovell; Juan Chen; Gang Zheng
Tumor hypoxia is increasingly being recognized as a characteristic feature of solid tumors and significantly complicates many treatments based on radio-, chemo-, and phototherapies. While photodynamic therapy (PDT) is based on photosensitizer interactions with diffused oxygen, photothermal therapy (PTT) has emerged as a new phototherapy that is predicted to be independent of oxygen levels within tumors. It has been challenging to meaningfully compare these two modalities due to differences in contrast agents and irradiation parameters, and no comparative in vivo studies have been performed until now. Here, by making use of recently developed nanostructured self-quenched porphysome nanoparticles, we were able to directly compare PDT and PTT using matched light doses and matched porphyrin photosensitizer doses (with the photosensitizer being effective for either PTT or PDT based on the existence of nanostructure or not). Therefore, we demonstrated the nanostructure-driven conversion from the PDT singlet oxygen generating mechanism of porphyrin to a completely thermal mechanism, ideal for PTT enhancement. Using a novel hypoxia tumor model, we determined that nanostructured porphyrin PTT enhancers are advantageous to overcome hypoxic conditions to achieve effective ablation of solid tumors.
Nature Nanotechnology | 2015
Elizabeth Huynh; Ben Y. C. Leung; Brandon Helfield; Mojdeh Shakiba; Julie-Anne Gandier; Cheng S. Jin; Emma R. Master; Brian C. Wilson; David E. Goertz; Gang Zheng
Converting nanoparticles or monomeric compounds into larger supramolecular structures by endogenous or external stimuli is increasingly popular because these materials are useful for imaging and treating diseases. However, conversion of microstructures to nanostructures is less common. Here, we show the conversion of microbubbles to nanoparticles using low-frequency ultrasound. The microbubble consists of a bacteriochlorophyll-lipid shell around a perfluoropropane gas. The encapsulated gas provides ultrasound imaging contrast and the porphyrins in the shell confer photoacoustic and fluorescent properties. On exposure to ultrasound, the microbubbles burst and form smaller nanoparticles that possess the same optical properties as the original microbubble. We show that this conversion is possible in tumour-bearing mice and could be validated using photoacoustic imaging. With this conversion, our microbubble can potentially be used to bypass the enhanced permeability and retention effect when delivering drugs to tumours.
Angewandte Chemie | 2012
Jonathan F. Lovell; Cheng S. Jin; Elizabeth Huynh; Thomas D. MacDonald; Weiguo Cao; Gang Zheng
We recently reported that porphyrin–phospholipid conjugates can self-assemble into “porphysome” nanovesicles composed of a dense porphyrin bilayer. Porphysomes exhibit structurally driven nanoscale optical properties and have intrinsic capabilities for multimodal imaging, drug delivery, and photothermal therapy. Previous studies were based on porphysomes formed from a mixture of two chemically similar phospholipid–porphyrin regioisomers. However, use of a mixture of regioisomers is far from ideal for robust nanoparticle characterization in vitro and in vivo. In general, difficulties in synthesizing, detecting, and distinguishing phospholipid regioisomers have prevented examination of their in vivo fate until now. To our knowledge, the results reported herein are the first to demonstrate in vivo enzymatic biodegradability for any intrinsically optically active nanoparticle, a feature that might be important when considering the use of new nanomaterials in human clinical trials. Chemically modified phospholipids have proven useful for diverse biotechnology applications. Phospholipids can be labeled at various positions on their head group or side chain. While head-group modification can readily be achieved using the primary amine group of phosphatidylethanolamine, side-chain modification is less straightforward but is appropriate for conjugating more hydrophobic ligands while maintaining an amphipathic phospholipid character. Recently, phospholipids modified with cholesterol, retinoic acid, and porphyrin side chains have been developed that display useful properties for drug-delivery, immunological, and biophotonic applications. Synthesis of single sidechain-modified phospholipids is often affected by acyl migration of the side chains. The resulting regioisomers (e.g., Figure 1a) have similar structures, which make their separation impractical and their detection challenging or impossible using techniques such as HPLC, NMR spectroscopy, and mass spectrometry. Regioselective phospholipid side-chain modification has been achieved using a number of techniques. Synthesis of modified phospholipids has been performed in multistep reactions using a modified glycerol backbone, with protecting groups sometimes being required. Acylation of lyso-
Advanced Healthcare Materials | 2014
Cheng S. Jin; Liyang Cui; Fan Wang; Juan Chen; Gang Zheng
Photodynamic therapy (PDT) and photothermal therapy (PTT) possess advantages over the conventional therapies with additional treatment selectivity achieved with local laser irradiation. Comparing to PTT that ablates target tissue via thermal necrosis, PDT induces target cell death via singlet oxygen without damaging the underling connective tissue, thus preserving its biological function. Activatable photosensitizers provide an additional level of treatment selectivity via the disease-associated activation mechanism. In this study, folate-conjugated porphysomes are introduced as targeting-triggered activatable nano-sized beacons for PDT. Porphysomes are reported previously as the most stable and efficient delivery system of porphyrin, but their nanostructure converts the singlet oxygen generation mechanism to thermal ablation mechanism. By folate-receptor-mediated endocytosis, folate-porphysomes are internalized into cells rapidly and resulted in efficient disruption of nanostructures, thus switching back on the photodynamic activity of the densely packed porphyrins for effective PDT. In both in vitro and in vivo studies, folate-porphysomes can achieve folate receptor-selective PDT efficacy, which proves the robustness of targeting-triggered PDT activation of porphysome nanostructure for highly selective tumor ablation. The formulation of porphysomes can be modified with other targeting ligands as activatable photosensitizers for personalized treatment in future.
ACS Nano | 2013
Tracy W. Liu; Thomas D. MacDonald; Cheng S. Jin; Joseph M. Gold; Robert G. Bristow; Brian C. Wilson; Gang Zheng
Prostate cancer is the most common cancer among men and the second cause of male cancer-related deaths. There are currently three critical needs in prostate cancer imaging to personalize cancer treatment: (1) accurate intraprostatic imaging for multiple foci and extra-capsular extent; (2) monitoring local and systemic treatment response and predicting recurrence; and (3) more sensitive imaging of occult prostate cancer bone metastases. Recently, our lab developed porphysomes, inherently multimodal, all-organic nanoparticles with flexible and robust radiochemistry. Herein, we validate the first in vivo application of 64Cu-porphysomes in clinically relevant orthotopic prostate and bony metastatic cancer models. We demonstrate clear multimodal delineation of orthotopic tumors on both the macro- and the microscopic scales (using both PET and fluorescence) and sensitively detected small bony metastases (<2 mm). The unique and multifaceted properties of porphysomes offers a promising all-in-one prostate cancer imaging agent for tumor detection and treatment response/recurrence monitoring using both radionuclide- and photonic-based strategies.
Lasers in Surgery and Medicine | 2011
Cheng S. Jin; Gang Zheng
In photodynamic therapy (PDT), photosensitizers are activated by light of a specific wavelength and produce cytotoxic molecules to damage diseased tissues. Most photosensitizers are hydrophobic and easily aggregate in aqueous solution. To maintain their photodynamic activity and to enhance delivery efficiency of photosensitizers, various pharmaceutical carriers and delivery systems have been investigated for photosensitizers. This review will focus on liposomal nanostructures for the delivery of photosensitizing agents.
Bioconjugate Chemistry | 2014
Elizabeth Huynh; Cheng S. Jin; Brian C. Wilson; Gang Zheng
Microbubbles (MBs) are currently used as ultrasound (US) contrast agents and as delivery vehicles for site-specific US-triggered drug and gene delivery. Multimodal US-based imaging methods have been applied preclinically to assess and validate the effectiveness and fate of MBs in imaging and therapy. Here we present the first intrinsically trimodal MBs by incorporating a dense concentration of porphyrin molecules within a MB shell, enabled by the use of a single porphyrin-lipid component. These MBs possess US, photoacoustic, and fluorescence properties that are demonstrated in solution and in a mouse tumor xenograft model. They also have potential to be extended to other imaging modalities such as magnetic resonance imaging and nuclear imaging.
Small | 2014
Qiaoya Lin; Cheng S. Jin; Huang Huang; Lili Ding; Zhihong Zhang; Juan Chen; Gang Zheng
The abilities to deliver siRNA to its intended action site and assess the delivery efficiency are challenges for current RNAi therapy, where effective siRNA delivery will join force with patient genetic profiling to achieve optimal treatment outcome. Imaging could become a critical enabler to maximize RNAi efficacy in the context of tracking siRNA delivery, rational dosimetry and treatment planning. Several imaging modalities have been used to visualize nanoparticle-based siRNA delivery but rarely did they guide treatment planning. We report a multimodal theranostic lipid-nanoparticle, HPPS(NIR)-chol-siRNA, which has a near-infrared (NIR) fluorescent core, enveloped by phospholipid monolayer, intercalated with siRNA payloads, and constrained by apoA-I mimetic peptides to give ultra-small particle size (<30 nm). Using fluorescence imaging, we demonstrated its cytosolic delivery capability for both NIR-core and dye-labeled siRNAs and its structural integrity in mice through intravenous administration, validating the usefulness of NIR-core as imaging surrogate for non-labeled therapeutic siRNAs. Next, we validated the targeting specificity of HPPS(NIR)-chol-siRNA to orthotopic tumor using sequential four-steps (in vivo, in situ, ex vivo and frozen-tissue) fluorescence imaging. The image co-registration of computed tomography and fluorescence molecular tomography enabled non-invasive assessment and treatment planning of siRNA delivery into the orthotopic tumor, achieving efficacious RNAi therapy.
Clinical Cancer Research | 2016
Nidal Muhanna; Liyang Cui; Harley Chan; Laura Burgess; Cheng S. Jin; Thomas D. MacDonald; Elizabeth Huynh; Fan Wang; Juan Chen; Jonathan C. Irish; Gang Zheng
Purpose: The low survival rate of head and neck cancer (HNC) patients is attributable to late disease diagnosis and high recurrence rate. Current HNC staging has inadequate accuracy and low sensitivity for effective diagnosis and treatment management. The multimodal porphyrin lipoprotein-mimicking nanoparticle (PLP), intrinsically capable of positron emission tomography (PET), fluorescence imaging, and photodynamic therapy (PDT), shows great potential to enhance the accuracy of HNC staging and potentially HNC management. Experimental Design: Using a clinically relevant VX-2 buccal carcinoma rabbit model that is able to consistently develop metastasis to regional lymph nodes after tumor induction, we investigated the abilities of PLP for HNC diagnosis and management. Results: PLPs facilitated accurate detection of primary tumor and metastatic nodes (their PET image signal to surrounding muscle ratios were 10.0 and 7.3, respectively), and provided visualization of the lymphatic drainage from tumor to regional lymph nodes by both preoperative PET and intraoperative fluorescence imaging, allowing the identification of unknown primaries and recurrent tumors. PLP-PDT significantly enhanced cell apoptosis in mouse tumors (73.2% of PLP-PDT group vs 7.1% of PLP alone group) and demonstrated complete eradication of primary tumors and obstruction of tumor metastasis in HNC rabbit model without toxicity in normal tissues or damage to adjacent critical structures. Conclusions: PLPs provide a multimodal imaging and therapy platform that could enhance HNC diagnosis by integrating PET/computed tomography and fluorescence imaging, and improve HNC therapeutic efficacy and specificity by tailoring treatment via fluorescence-guided surgery and PDT. Clin Cancer Res; 22(4); 961–70. ©2015 AACR.